



Disclosure of Management Transaction according to the Art. 19 of Regulation (EU) No. 596/2014

Peania, 20 March 2023 – Lavipharm S.A. (hereinafter referred to as «**Lavipharm**»), pursuant to article 19 of Regulation (EU) No. 596/2014, and following a relevant notification, announces that Mr. Vasileios Baloumis, Group CFO:

-on 16 March purchased 15,000 common shares of Lavipharm, of a total value of EUR 5,758.49 and

-on 17 March purchased 23,455 common shares of Lavipharm of a total value of EUR 9,076.23.

###